← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

BIOCERES CROP SOLUTIONS CORP. (BIOX)

Materials • NASDAQ

$0.43

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

10.0/100

POOR BUSINESS

BIOCERES CROP SOLUTIONS CORP. (BIOX) scores 10/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full BIOX quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

Margin of Safety unavailable — insufficient data for the owner-earnings DCF.

BRINA GAP ↗

Is the market underestimating or overestimating what this business is capable of going forward?

-27.8%

Market Overestimates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full BIOX valuation analysis · → View full BIOX Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-82.4%)

Debt-to-Equity (Solvency Risk):GOOD (0.53x)

Operating Margin (Operational Efficiency):CRITICAL (0.8%)

Return on Capital (Capital Efficiency):CRITICAL (0.4%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

BIOCERES CROP SOLUTIONS CORP. (BIOX) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, BIOCERES CROP SOLUTIONS CORP. (BIOX) shows a Brina Gap of -27.8%, which weakens the case: based on the company's ROIC (0.4%) and reinvestment rate (129.7%), the business can fundamentally grow at 0.5% — but the current enterprise value implies the market expects 28.4%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.43

Market Cap:$27.19M

Valuation Multiples (3)

P/B Ratio:0.09x

P/S Ratio:0.09x

Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$152.42M

Ev Ebitda Ratio:69.07x

Pfcf Ratio:0.59x

Price Action & Momentum (1)

% of 52-Week High:14.6%

B. Profitability Assessment

Return Metrics (7)

ROE:

-82.4%

📊 Click to view full BIOX ROE analysis →

ROA:-31.8%

Roic:

0.4%

📊 Click to view full BIOX ROIC analysis →

Reinvestment Rate:129.7%

Fundamental Growth Rate (g):0.5%

Market-Implied Growth Rate:28.4%

Brina Gap:

-27.8%

☷ Click to view full BIOX Brina Gap analysis →

Margin Analysis (3)

Operating Margin Ttm:0.8%

Net Margin Ttm:-84.9%

Ebitda Margin:0.8%

TTM Performance (3)

Gross Margin Ttm:39.1%

Operating Margin Ttm:0.8%

Net Margin Ttm:-84.9%

Yield Metrics (2)

Earnings Yield:-$854.61

Dividend Yield:0.3%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-4.00

📊 Click to view full BIOX Earnings Surprise analysis →

EPS Surprise vs Expected:-2,114.4%

Latest Earnings Filed:2026-03-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):4.7%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-23.4%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-21.4%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.91x

Quick Ratio:0.65x

Cash Ratio:0.10x

Leverage Analysis (3)

Debt To Equity Ttm:0.53x

Debt-to-Equity Ratio:0.53x

Debt To Ebitda:71.57x

Coverage Ratios (2)

Interest Coverage Ratio:-0.07x

Times Interest Earned:-0.07

Capital Structure (4)

Working Capital:-29,674,474.00

Cash And Cash Equivalents:32,695,079.00

Long Term Debt:$38.20M

Net Debt:$125.23M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $286.54M

Linear Growth: 4.7%

📊 Click to view full BIOX Revenue analysis & methodology →

Cost Of Revenue Ttm:$174.53M

Profitability Breakdown (2)

Gross profit TTM: $112.01M

Linear Growth: -20.7%

📊 Click to view full BIOX Gross Profit analysis & methodology →

Operating income TTM: $2.21M

Linear Growth: -21.4%

📊 Click to view full BIOX Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: -$243.17M

Linear Growth: -23.4%

📊 Click to view full BIOX Net Income analysis & methodology →

Income Before Tax:$0.00

Ebitda Ttm:2,206,739.00

Operating Expenses (5)

Operating Expenses:0.00

R And D Expense:0.00

Sga Expense:0.00

Income Tax Expense:$7.93M

Interest Expense:31,311,820.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:0.0%

Ebitda Margin:0.8%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$763.65M

Current Assets:$308.31M

Ppe Net:74,575,386.00

Goodwill:112,163,432.00

Intangible Assets:$181.17M

Liability Structure (4)

Total Liabilities:468,426,518.00

Current Liabilities:337,985,971.00

Long Term Debt:$38.20M

Short Term Debt:$119.73M

Equity & Capital (3)

Equity:$295.22M

Retained Earnings:$0.00

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:207,320,974.00

Inventory:87,611,269.00

Accounts Payable:87,073,151.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

$49.91M$47.76M

Investment Activities (1)

Investing Cash Flow:-$1.26M

Financing Activities (3)

Financing Cash Flow:-$28.71M

Dividends Paid Ttm:72,051.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.78

Eps diluted TTM: -$3.78

Linear Growth: -36.1%

📊 Click to view full BIOX EPS analysis & methodology →

Earnings Per Share Ttm:-$3.85

Revenue & Cash Per Share (2)

Sales Per Share Ttm:4.53

Operating Cash Flow Per Share:$0.79

Book Value & Capital (2)

Book Value Per Share:$4.67

Cash Per Share:0.52

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.38x

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:1.38x

Days Sales Outstanding Ttm:264.09

Inventory Management (2)

Inventory Turnover Ttm:1.99x

Days Inventory Outstanding Ttm:183.22

Payables & Cash Cycle (2)

Days Payable Outstanding:182.10

Cash Conversion Cycle:265.21

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00

Quality Score:45.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:129.7%

Fundamental Growth Rate (g):0.5%

Market-Implied Growth Rate:28.4%

Brina Gap:

-27.8%

☷ Click to view full BIOX Brina Gap analysis →

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):4.7%

Net Income Growth Rate (Linear):-23.4%

Operating Income Growth Rate (Linear):-21.4%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):-20.7%

C. Company Profile & Context

Corporate Information (6)

Symbol:BIOX

Company Name:BIOCERES CROP SOLUTIONS CORP.

Sector:Materials

Industry:Chemicals

Exchange:NASDAQ

Country:Cayman Islands

Market Classification (3)

Market Cap Category:N/A

Price Category:penny

Volume Category:N/A

Share Structure (3)

Shares Outstanding:63.23M

Shares Outstanding Basic:0

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 08:43:51 UTC

Data Timestamp:2026-08-20T22:02:41.975706